Context: Maturity-onset diabetes of the young type 5 (MODY5) is caused by mutations of the hepatocyte nuclear factor 1 homeobox b gene (HNF1B). Although clinical characteristics and therapeutic management of MODY5 are increasingly better defined, adequate consideration of the frequent association of MODY5 with 17q12 deletion syndrome is often missing.
M aturity-onset diabetes of the young (MODY) describes rare autosomal dominant monogenic subtypes of clinically heterogeneous diabetes mellitus (DM) manifestations and accounts for at least 1% to 2% of DM diagnoses (1) . The most frequent mutations in patients with MODY are found in genes encoding the hepatocyte nuclear transcription factor 1 homeobox a (HNF1A: MODY3; 58%), glucokinase (GCK: MODY2; 22%), and hepatocyte nuclear factor 4 homeobox (HNF4A: MODY1; 5%) (1) .
Mutation of the transcription factor HNF1b gene causes MODY5, a rare subgroup (2% to 6% of MODY diagnoses) that is typically characterized by additional extrapancreatic clinical features (2) .
HNF1b belongs to the homeobox-containing family of transcription factors and plays a central role in the development of the pancreas, the kidneys, and the liver (3) . The first HNF1B mutation with manifestation of MODY5 was described in 1997 (4) . Since then, a great variety of clinical phenotypes have been described. Until now, .50 different mutations have been reported within the HNF1B gene, located on chromosome 17q12 (2) . The most common mutation, occurring in 50% of patients with MODY5, is a whole gene deletion. This HNF1B deletion was recently associated with 17q12 deletion syndrome in virtually all cases (5) .
The 17q12 deletion syndrome represents a rare yet recurrent chromosomal aberration with deletion of a 1.4 Mb-spanning DNA sequence on the long arm of chromosome 17. This syndrome is characterized by the combination of kidney or urinary tract malformations, DM, and neurodevelopmental or neuropsychiatric disorders (6) .
Because of the rarity of this genetic disease, clinical characteristics of 17q12 deletion syndrome and common recommendations for its evaluation in patients with MODY5 are still poorly defined. With the presentation of two cases of 17q12 deletion syndrome and review of all pertinent literature, we discuss the clinical presentation, adequate diagnostic approaches, and therapeutic management of patients with 17q12 deletion syndrome.
Methods
Both patients have given their informed written consent for publication of these case reports.
Case Presentation

Case 1
This female patient presented to the Division of Endocrinology and Diabetology of the University Hospital of Freiburg, Germany, at the age of 16 years. Her medical history was characterized by prenatal diagnosis of polycystic kidney disease with consecutive left-sided nephrectomy as an infant. She displayed reduced intellectual performance compared with that of other family members (including two sisters). DM was detected at the age of 14 years and since then treated with metformin (500 mg bid) and repaglinide (NovoNorm TM ; 1 mg at mealtimes). DM type 1 was excluded by negative antibody testing (antiglutamic acid decarboxylase, anti-islet antigen-2, and antiinsulin antibodies). However, because of the rejection of offered genetic testing by the patient and her family, the etiology of her diabetes initially remained unclear. Considering a rather cachectic nutritional status (1.65 m, 47 kg), there were no indications of relevant insulin resistance. Furthermore, no related family members were known to have DM. Three years after the diagnosis of DM, the patient developed insulin dependency and was treated by intensified insulin therapy (insulin glargine and insulin lispro). Apart from repeated blood sugar imbalances, mainly due to noncompliance, blood tests showed relapsing elevation of liver enzymes. There were no known familial liver diseases. Hepatitis B and C and autoimmune diseases as well as toxic causes of hepatopathy could be excluded. Even liver biopsy and the following histologic evaluation of the liver tissue were not indicative.
At the age of 26 years, the patient was willing to undergo genetic testing. Deletion of exons 1-9 of HNF1B as well as 17q12 deletion syndrome were verified by microarray analysis [ Fig. 1(a) ]. Ultimately, targeted diagnostic workup by abdominal MRI revealed pancreatic atrophy [ Fig. 2 (a) and 2(b)], whereas a gynecological examination excluded structural genital malformations.
Case 2
The second patient, a 36-year-old woman, was admitted to the Division of Endocrinology and Diabetology at the University Hospital of Freiburg because of unclear acute kidney failure as well as hepatopathy and previously diagnosed MODY5.
Abdominal pain and hepatopathy had already led to an inpatient stay in a regional hospital only 3 months earlier. The diagnostic investigations in this hospital excluded viral, autoimmune, and toxic causes for the elevation in liver enzymes. Liver biopsy showed slight periportal fibrosis and steatosis but could not pinpoint a clear etiology for the cholestatic hepatopathy. However, as an incidental finding, glycated hemoglobin of 7.0% was detected, leading to the diagnosis of DM. Genetic examination by multiplex ligation-dependent probe amplification displayed a heterozygous deletion of exons 1-9 of the HNF1B gene, thus genetically confirming MODY 5. Since then, DM has been treated by dietary restriction and preprandial injections of short-acting insulin (insulin lispro, 10 to 20 IU per day). At time of admission to our department, the patient's alanine aminotransferase and alkaline phosphatase levels were elevated 10-fold, and her serum creatinine level was 1.2 mg/dL. Apart from showing multiple uncomplicated cysts at the lower pole of the left kidney, abdominal ultrasonography was inconspicuous. Four days after patient admission, the laboratory abnormalities again improved spontaneously. A second assessment of the previously performed liver biopsy identified a paucity of intrahepatic bile ducts (Fig. 3) and excluded amyloidosis, Wilson disease, and hemochromatosis. MRI of the abdomen, including magnetic resonance cholangiopancreatography, displayed unsuspicious liver imaging but revealed pancreatic atrophy with cystic formations in the residual pancreas head and no pancreas tissue corresponding to the pancreatic tail and corpus [ Fig. 2 Because of the suspicious phenotype of the patient, with downslanted palpebral fissures and frontal bossing (Fig. 4) , combined with mild intellectual disability as uncommon features of pure HNF1B mutation, we referred her to the Institute for Human Genetics of our University Hospital to test for 17q12 deletion syndrome. Indeed, microarray analysis confirmed a heterozygous deletion of a 1.58-Mb-spanning DNA sequence at chromosomal localization 17q12 [ Fig.  1(b) ]. Moreover, a copy number variation of unknown significance, namely heterozygous microduplication of 1.04 Mb at 10q11. 22 , was an incidental finding. Gynecological investigation further excluded structural genital malformations.
After verification of 17q12 deletion syndrome, regular follow-up examinations, including blood and urine testing as well as abdominal ultrasonography with interdisciplinary review of the results, were planned for both patients every 6 months at the outpatient clinic of the Division of Endocrinology and Diabetology at the University Hospital of Freiburg.
Molecular genetic testing of two patients
The older patient was previously diagnosed with HNF1B deletion through multiplex ligation-dependent probe amplification at an external institute for human genetics. On conventional karyotyping, both of our patients had a normal female karyotype 46,XX. To confirm the deletion on the long arm of chromosome 17 and determine the magnitude of the deletion, genomic DNA of the patients was examined by microarray analysis (CytoSure TM Constitutional v3 Array 180k, OGT) according to the manufacturer's instructions. After hybridization, the array was scanned by the SureScan Microarray scanner (Agilent Technologies, Santa Clara, CA), and the results were analyzed using CytoSure Interpret software v.4.9 (OGT) and the Genome Reference Consortium human genome GRCh37 (hg19). Molecular karyotyping revealed a comparable deletion of approximately 1.58 Mb (174 contiguous oligonucleotides) in 17q12 in both patients ( Fig. 2) , as well as a microduplication of 1.04 Mb at 10q11.22 in patient 2 (not shown).
Literature review
A full review was performed of the published literature up to February 2018 indexed in PubMed regarding DM type MODY5 and 17q12 deletion syndrome. Search terms included 17q12 deletion syndrome, diabetes mellitus type MODY5, and HNF1B. Overall, 361 published cases with genetically verified HNF1B deletion or 17q12 deletion syndrome were assessed.
Discussion
The 17q12 deletion syndrome represents a rare genetic syndrome characterized by the combination of DM type MODY5 and structural or functional abnormalities of the kidneys as well as neuropsychiatric or neurodevelopmental disorders (6) . Although the association of DM and renal dysfunction in patients with HNF1B mutations is commonly known as renal cysts and diabetes syndrome, the frequent overlap of HNF1B mutations with 17q12 deletion syndrome is often underrecognized. However, Laffargue et al. (5) only recently reported association of HNF1B deletion with 17q12 deletion syndrome in virtually all cases. Because whole HNF1B deletions are the most common cause of MODY5, all patients with suspected MODY5 should be examined for common clinical features of 17q12 deletion syndrome to perform specific microarray testing of the 1.4-Mb deletion on chromosome 17q12. In the following paragraph, we discuss the pathogenesis of this microdeletion syndrome, as well as its recommended diagnostic and therapeutic management based on previously defined syndromal features involving the kidneys, pancreas, brain, and gastrointestinal and genital tracts.
Genetic diagnosis and characterization of 17q12 deletion syndrome
The 17q12 deletion syndrome represents an extremely rare microdeletion syndrome with an estimated prevalence of 1.6 per 100,000 citizens, with high penetrance and variable expressivity (7) . Chromosomal microdeletions can either be inherited from an affected parent in an autosomal dominant manner or appear de novo. In fact, de novo mutations are responsible for 70% of 17q12 deletion syndrome cases (6) . Thus, the absence of DM and other typical clinical features in parents and other relatives does not exclude 17q12 deletion syndrome as a possible diagnosis. Accordingly, the parents of both of our patients did not show signs of 17q12 deletion syndrome. Possible pathogenic mechanisms of microdeletions are loss of chromosomal material in cases of familial balanced translocations, chromosomal crossover within a chromosomal inversion, unequal crossing over, and chromosomal breaking without rejoining. Deletion in 17q12 deletion syndrome is mediated by aberrations during homologous recombination. Because the exogenic region on 17q12 is encompassed by segmental duplications, all patients with this syndrome exhibit the same unique genetic sequence of 1.4 Mb, including HNF1B, ACACA, and LHX1, as seen in our reported cases of two affected females without consanguinity. The risk for inheritance of this deletion in the offspring of affected patients is 50% (6) . Consequently, all patients suspected of having or diagnosed with 17q12 deletion syndrome should be offered genetic counseling.
17q12 deletion syndrome-associated kidney disease
Structural or functional kidney dysfunctions are characteristic of HNF1B mutations and are well described. The most common manifestations are multicystic dysplastic kidneys as reported in our casesplease check renumbering in the text and table for accuracy. (90%) ( Table 1 ). Other possible renal features are poor corticomedullary differentiation, hydronephrosis, or dilated ureter. Renal function ranges from normal kidney function (59%) to chronic kidney failure (41%), including cases of severe renal impairment requiring dialysis (25) . Renal dysfunction is accompanied by hypomagnesemia and/or hypocalciuria in 74% of cases. Affected patients require regular laboratory renal function tests as well as abdominal ultrasonography of the kidneys (26) .
The molecular basis of HNF1B mutation-induced nephropathy lies in the function of this transcription factor as a regulator of various genes involved in kidney development. Appropriately, HNF1B knockout mice develop renal cysts and dilation of the ureter (27) .
Given the assumption of HNF1B haploinsufficiency as the underlying pathogenic mechanism, the reported genotype/phenotype correlations are surprising. Thus, Dubois-Laforgue et al. (8) only recently reported higher estimated glomerular filtration rate and lower frequency of chronic kidney disease stage 3 and 4/endstage renal disease in patients with HNF1B deletion at diagnosis than in patients with intragenic HNF1B mutations. These observations are supported by the findings of Heidet et al. (28) and Clissold et al. (9) . Two hypotheses aim to explain this observation: first, the possibility of a dominant negative effect of some intragenic HNF1B mutations, and second, a protective effect for the kidney from other genes included in the 17q12 deletion region (8, 29) . Future studies are needed to clarify these findings. 17q12 deletion syndrome-associated DM As described for intragenic HNF1B mutations, DM represents a frequent feature of 17q12 deletion syndrome and affects 63% of these patients. DM thereby follows common characteristics of MODY5. Diagnosis is often made before the age of 40 years and is based on slow development of insulin dependency (25) . DuboisLaforgue et al. (8) reported residual insulin secretion in 80% of patients with HNF1B intragenic or whole-gene mutations, defined as fasting C peptide level .0.20 nmol/L or stimulated C peptide level .0.50 nmol/L. However, development of insulin dependency was observed in 79% within 10 years of follow-up. Consequently, although ;50% of patients can initially be treated with oral antidiabetics, decline of endocrine pancreatic function as well as progress of nephropathy result in the need for insulin supplementation.
To date, there are no systematic analyses of differences in insulin secretion capacity and progress of insulin dependency between patients with intragenic mutations and those with whole-gene mutations. However, compared with patients with intragenic HNF1B mutations, patients with 17q12 deletion syndrome have a lower body mass index and more frequently required treatment with insulin at diabetes diagnosis (8) .
The molecular mechanisms for dysfunctional blood glucose control due to HNF1B mutations are not conclusively clarified at the molecular level; however, HNF1B expression has been shown to affect prandial insulin secretion, suggesting impairment of pancreatic beta cell integrity and/or function and thus insulin biosynthesis (30) .
17q12 deletion syndrome-associated pancreatic malformation
In both presented cases of patients with 17q12 deletion syndrome, MRI revealed complete atrophy of the pancreatic body and tail. Although the pancreatic head of patient 1 had normal configuration, patient 2 additionally showed cystic enlargement of the pancreatic head.
The development of the pancreas starts at the fourth week of gestation by formation of two separate endodermal buds from the caudal duodenum. The ventral bud forms the head and processus uncinatus, whereas the body and the tail of the pancreas arise from the dorsal bud (31) . Agenesis of the ventral pancreas is not compatible with life (32) . Agenesis of the dorsal pancreas is an extremely rare disease, with ,50 cases reported worldwide (33) . However, Haldorsen et al. (34) previously reported that pancreas atrophy was associated with HNF1B mutations and assumed a major role for this transcription factor in the formation of the dorsal pancreas. Although older publications state an estimated prevalence of 20% (6), our review of the latest literature actually revealed that pancreatic malformation represents a frequent clinical feature in patients with 17q12 deletion syndrome as well (52%) ( Table 1) . Because the transcription factor HNF1B is known to regulate gene expression patterns in pancreatic organogenesis and pancreatic atrophy occurs in patients with simple HNF1B mutations to the same extent, pancreatic malformation in patients with 17q12 deletion syndrome can be attributed to HNF1B gene deletion (34) . Consequently, pancreas morphology and exocrine function do not differ between patients with HNF1B intragenic mutations and those with deletions (8) .
Although endocrine dysfunction constitutes one of the defining clinical manifestations of 17q12 deletion syndrome, impairment of exocrine pancreatic function is highly variable. Neither of our patients showed signs of exocrine pancreatic insufficiency, confirmed by normal levels of fecal elastase. In contrast, Dubois-Laforgue et al. (8) reported exocrine pancreas dysfunction in 29 of 38 investigated patients (78%), and our review also revealed a frequency of 69% in all reported cases of HNF1B deletion (Table 1) . Other known clinical manifestations of pancreatic atrophy are chronic pancreatitis and pancreatic tumors (35) . As a possible clinical sign of pancreatitis, one of our patients reported relapsing abdominal pain. However, blood tests showed normal levels of amylase and lipase, and MRI did not show other signs of chronic pancreatitis such as calcifications. The risk of malignant pancreatic tumors in patients with 17q12 deletion syndrome and agenesis of the dorsal pancreas is thought to be strikingly increased, even though systematic investigations are missing (35) .
17q12 deletion syndrome-associated neurologic disorders
Neurologic abnormalities, including developmental delay and neuropsychiatric disorders, are characteristic symptoms in patients with 17q12 deletion syndrome (58% and 27%, respectively) ( Table 1) . Because functional cerebral gene expression is not known for the transcription factor HNF1b, in contrast to DM and kidney malformations, neurologic anomalies are hardly explainable by simple HNF1B mutation without microdeletion. This assumption is supported by the study of Clissold et al. (9) , who reported that 17q12 deletions but not HNF1B mutations were associated with neurodevelopmental disorders. Consequently, neurologic developmental delay and psychiatric disorders seem to be induced by dysfunction of affected neighboring genes and should always indicate genetic testing for 17q12 deletion syndrome when observed in patients with MODY5. 17q12 deletion typically encompasses the genes LHX1 and ACACA. LHX1 is expressed in the brain in early development and therefore represents a candidate gene for the neurocognitive phenotype. Indeed, LHX1 plays a role in the differentiation of neural cells and the transcriptional control of axonal guidance and has been associated with epilepsy, autism, and mental retardation (7, 36, 37) . ACACA encodes acetyl-CoA carboxylase a, a key enzyme in fatty acid metabolism. ACACA is ubiquitously expressed, and reduced expression in the brain has been associated with neurodegenerative diseases (38, 39) and autism (37) . However, the exact pathophysiological mechanisms underlying these associations are unknown.
Altogether, patients with 17q12 microdeletion often show mental retardation and are at high risk for autism and schizophrenia (10) . Even structural brain malformations have been described (7) . Consequently, neuropsychiatric evaluation should be performed in all patients. Only in the presence of severe neurologic or psychiatric symptoms do we recommend MRI of the brain to exclude structural brain malformations. 17q12 deletion syndrome-associated hepatopathy Hepatopathy is a common feature in patients with 17q12 deletion syndrome, as well as in patients with simple HNF1B mutations, and affects 65% of patients with HNF1B deletions, as reported in the literature (Table 1) . Hepatopathy is typically characterized by elevations of aspartate aminotransferase and alkaline phosphatase, sometimes accompanied by mild hyperbilirubinemia (11) . Liver imaging abnormalities, assessed by ultrasonography or CT scan, are rather infrequent and often nonspecific (8) . Liver biopsies of patients with HNF1B mutations typically show variable manifestations of intrahepatic bile duct rarefication, steatosis, and periportal fibrosis (11) . However, because rarefications of intrahepatic bile ducts are frequently moderate, histologic evaluation of liver biopsies is highly dependent on targeted investigation. As a result, liver biopsies of patients with cholestatic hepatopathy and known HNF1B mutations are frequently reported to exhibit only nonspecific alterations (11) . Appropriately, the histologic evaluation of the liver biopsies of the reported cases showed a decreased number of bile ducts.
Mice models confirm gene expression of HNF1b in the liver, gall bladder, and intrahepatic bile ducts through early organogenesis (40) . Studies verified intrahepatic biliary duct malformation and jaundice induced by liverspecific HNF1B deletion in mice (41) . Although association of mutations of the related transcription factor HNF1a with malignant liver tumors has been reported (42), the risks of liver cirrhosis and liver cancer in patients with HNF1B mutation and 17q12 deletion syndrome are unknown. However, cases reported in the literature usually show mild liver dysfunction. Excretory liver functions are typically not affected (11) . Furthermore, the first patient in this case report did not show progress of cholestatic hepatopathy within 8 years of follow-up. Therefore, we propose regular laboratory monitoring and avoidance of liver-damaging toxins as appropriate. However, potentially elevated risks of liver fibrosis or liver cirrhosis and hepatocellular carcinoma may be evaluated by abdominal ultrasonography twice a year, which is recommended for monitoring of structural and functional renal abnormalities in any event.
17q12 deletion syndrome-associated dysmorphic features, genital malformations, and associated genetic syndromes
Dysmorphic features in patients with 17q12 deletion syndrome are frequent but highly variable and are reported in 67% of cases ( Table 1 ). The second patient especially showed noticeable facial dysmorphism, with a high forehead, a flat midface, and downslanting palpebral fissures. Moreover, frontal bossing, a depressed nasal bridge and deep-set eyes, has been described in patients with 17q12 deletion syndrome (7, 43) . To the best of our knowledge, only two studies investigated the presence of and differences in dysmorphic features in patients with intragenic HNF1B mutations compared with those with HNF1B or 17q12 deletion syndrome, respectively. Although Clissold et al. (9) could not identify one single dysmorphic feature as more common in patients with 17q12 deletion syndrome, Laffargue et al. (5) stated that a high forehead, deep-set eyes, and chubby cheeks were more frequent in a group of patients with HNF1B deletions. However, in consensus, both studies reported more pronounced craniofacial dysmorphia in patients with 17q12 deletion syndrome when evaluated as a whole, indicating HNF1B-independent genetic contributions.
Genital malformations are seen in 50% of patients with 17q12 deletion syndrome and typically develop because of failed fusion of the Müllerian ducts. Consequently, 17q12 deletion syndrome was described as a risk factor for Mayer-Rokitansky-Küster-Hauser syndrome in females (44) . Other HNF1B deletion-associated abnormalities of the genital tract are bilateral or unilateral undescended testicles and bicornuate uterus (8, 9, 43) (Table 1) .
Interestingly, deletion of the 17q12 region has repeatedly been reported in combination with other genetic syndromes, namely prune-belly and Williams syndromes (12, 13) . Appropriately, the older patient in our cases showed additional microduplication at 10q11.22. This copy number variation has been associated with epilepsy, intellectual disability (45) , and obesity (46) . Because 17q12 deletion is also being associated with mental retardation, the impact of this copy number variation in the patient's neurological phenotype is elusive. However, these cases suggest potential genomic instability in patients with 17q12 deletion syndrome, and uncommon clinical symptoms should lead to extended genetic analysis.
Conclusion
In conclusion, 17q12 deletion syndrome represents an extremely rare genetic disease affecting multiple organ systems. Because MODY5 constitutes one of the major clinical features, evaluation of 17q12 deletion syndrome by diabetologists is of great importance. Only precise knowledge of the associated clinical features allows sufficient diagnostic and therapeutic management of these patients.
